A new target to induce MHC-I expression in lung adenocarcinoma

The Walter and Eliza Hall Institute of Medical Research (WEHI) received a $577,434 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period July 1, 2025 through June 30, 2028. The award supports research investigating a novel target to induce Major Histocompatibility Complex Class I (MHC-I) expression in lung adenocarcinoma. This research aligns with the program's focus on advanced biomedical research addressing critical health challenges relevant to military personnel and the broader public, with particular emphasis on cancer immunotherapy and the development of innovative therapeutic interventions.

As a recognized international research institution with established expertise in cancer immunology and advanced biomedical techniques, WEHI will conduct hypothesis-driven research aimed at identifying and validating therapeutic approaches to enhance MHC-I expression, a key mechanism for improving immune recognition and clearance of tumor cells. The three-year performance period allows the institute to progress from research development through potential translational applications in lung cancer treatment.